Conference Coverage

ASH 2014 Complete Coverage

Suboptimal Rate of Initial BRC-ABL1 Decline on Imatinib Signals Change in Inhibitor Warranted

Suboptimal Rate of Initial BRC-ABL1 Decline on Imatinib Signals Change in Inhibitor Warranted

Patients with high Sokal risk treated with imatinib have a higher rate of treatment failure and poorer molecular response.

Age, dPCR Analysis Predict Risk of Relapse in Leukemia Following Imatinib Discontinuation

Age, dPCR Analysis Predict Risk of Relapse in Leukemia Following Imatinib Discontinuation

Age less than 45 years of age and digital-PCR (dPCR) positivity are significantly associated with relapses in chronic myeloid leukemia (CML).

Presence of KIR2DL5B Gene Predicts Poor Response in Newly Diagnosed Chronic Leukemia

Presence of KIR2DL5B Gene Predicts Poor Response in Newly Diagnosed Chronic Leukemia

Presence of killer immunoglobulin-like receptor (KIR) genotype 2DL5B independently associated with poor response in chronic myelocytic leukemia (CML).

Inotuzumab Ozogamicin + MiniHCVD: New Standard of Care for Frontline Leukemia in Older Patients?

Inotuzumab Ozogamicin + MiniHCVD: New Standard of Care for Frontline Leukemia in Older Patients?

Combining inotuzumab ozogamicin with low-intensity chemotherapy achieved results better in newly diagnosed B-cell acute lymphoblastic leukemia (ALL).

Nilotinib Plus Chemotherapy Effective for First-Line Treatment of Acute Lymphoblastic Leukemia (ALL)

Nilotinib Plus Chemotherapy Effective for First-Line Treatment of Acute Lymphoblastic Leukemia (ALL)

Nilotinib in combination with chemotherapy is highly effective in Philadelphia chromosome-, BCR-ALB1-positive acute lymphocytic leukemia (ALL).

No Intensified Peg-Asparaginase Benefit in Standard Risk Acute Lymphoblastic Leukemia (ALL)

No Intensified Peg-Asparaginase Benefit in Standard Risk Acute Lymphoblastic Leukemia (ALL)

About 35% of standard risk B-acute lymphocytic leukemia (B-ALL) patients meet low risk criteria and are almost sure to be cured.

Brentuximab Vedotin Improves Survival in Hodgkin Lymphoma at Risk for Progression

Brentuximab Vedotin Improves Survival in Hodgkin Lymphoma at Risk for Progression

Brentuximab vedotin in Hodgkin lymphoma at risk for progression following autologous stem cell transplantation (ASCT) resulted in better survival.

Dasatinib Remains Effective In Imatinib-Resistant, -Intolerant Chronic-Phase Leukemia

Dasatinib Remains Effective In Imatinib-Resistant, -Intolerant Chronic-Phase Leukemia

Dasatinib continues to demonstrate durable efficacy and benefit during a 7-year follow-up for chronic-phase chronic myeloid leukemia (CML-CP).

Autologous Stem Cell Transplantation: 'Standard of Care' for HIV-Associated Lymphoma?

Autologous Stem Cell Transplantation: 'Standard of Care' for HIV-Associated Lymphoma?

Autologous hematopoietic stem cell transplantation (AHCT) should be considered standard of care for HIV-associated lymphoma.

Tosedostat Plus Cytarabine or Decitabine Induces Remission in Older Patients with AML/MDS

Tosedostat Plus Cytarabine or Decitabine Induces Remission in Older Patients with AML/MDS

Tosedostat with cytarabine or decitabine induced complete remission in acute myeloid leukemia (AML)/high-risk myelodysplastic syndrome (MDS).

Pacritinib's Lack of Myelosuppression May Be Due to Lack of JAK1, IRAK1 Inhibition

Pacritinib's Lack of Myelosuppression May Be Due to Lack of JAK1, IRAK1 Inhibition

Profile of pacritinib suggests potential role in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Proposed Prognostic Model for CNS Risk in Aggressive B-Cell Lymphoma Validated

Proposed Prognostic Model for CNS Risk in Aggressive B-Cell Lymphoma Validated

Investigators validated the German High-Grade Non-Hodgkin Lymphoma Study Group's new prognostic model for aggressive B-cell lymphoma.

R-CHOP Alone Induces High Complete Response in Non-Bulky Large B Cell Lymphoma

R-CHOP Alone Induces High Complete Response in Non-Bulky Large B Cell Lymphoma

Addition of radiotherapy should be reserved for the minority of patients with non-bulky limited-stage diffuse large B cell lymphoma (DLBCL).

Pomalidomide, Bortezomib, Dexamethasone Highly Effective in Lenalidomide-Refractory Multiple Myeloma

Pomalidomide, Bortezomib, Dexamethasone Highly Effective in Lenalidomide-Refractory Multiple Myeloma

Pomalidomide, bortezomib, and dexamethasone is a highly effective combination in multiple myeloma refractory to lenalidomide.

CTL019 Cells Demonstrate Strong Response in Pediatric Patients with Acute Lymphocytic Leukemia

CTL019 Cells Demonstrate Strong Response in Pediatric Patients with Acute Lymphocytic Leukemia

CTL019 cells cause strong, durable responses in pediatric patients with relapsed, refractory acute lymphocytic leukemia (ALL).

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs